Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 7, 2020

View Archived Issues

TXNIP inhibition nixes T2D

Supportive preclinical reported for PTX-COVID19-B vaccine candidate

First-in-human data presented for NTRX-07

Daiichi Sankyo patents new SIRT6 activators

Merck & Co. synthesizes HDAC inhibitors

Chinese researchers identify LPAR1 antagonists

Innate Tumor Immunity discloses NLRP3 agonists

New adenosine A2A receptor antagonists discovered by Nuvation Bio

Boehringer Ingelheim initiates first-in-human study of BI-764532

Structure-guided analysis unveils the mechanism of action of a dengue virus 2-specific inhibitor

SASS6 is involved in the proliferation of esophageal cancer and may be a novel therapeutic target

AstraZeneca is enrolling participants in phase I study of MEDI-8367

First patient enrolled in phase IIb/III study of ifenprodil for treatment of COVID-19

Six-month follow-up data announced from phase I study of INXN-4001

Anti-podocalyxin [225Ac]PODO-447 shows promise as immunotherapeutic for treating solid tumors

Dicerna provides data updates from clinical and preclinical developments

Topline data presented from phase III CARE-PWS study of LV-101

Phase II/III study of opaganib in patients with COVID-19 receives approval in Mexico

FDA clears IND for phase II study of TNX-102 SL

First patient dosed in a phase Ib/II study FGF-401 plus pembrolizumab

Study links mitochondrial DNA to abscopal response

Roche gives update on phase III IMpassion131 study of Tecentriq

GlycoNex initiates phase I study of GNX-102

First-in-human study of DC immunotherapy in patients with pancreatic adenocarcinoma

EC approves Xolair as treatment of severe chronic rhinosinusitis with nasal polyps

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...